IMRA

Bitwise MARA Option Income Strategy ETF
CAPPED RATING

IMARA Inc., a clinical-stage biopharmaceutical company, develops and commercializes therapeutics for patients with rare genetic disorders of hemoglobin. Its lead product candidate is IMR-687, an oral and once-a-day therapeutic that is in Phase 2b clinical trials for the treatment of sickle cell disease and ß-thalassemia. The company also develops IMR-261, an oral and clinical-ready activator of nuclear factor erythroid 2–related factor 2 for the treatment of hemoglobinopathies, iron disorders, and potentially other areas. IMARA Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

Bitwise MARA Option Income Strategy ETF (IMRA) is rated C- (2.1/5) on Deltasharpe Prism, scored against General sector peers. Its strongest pillar is Expenses (C+); its weakest is Momentum (D+).

Quantitative Factor Evaluation • Updated

Overall Rating
2.1 / 5.0
C-
Expenses
C+
Factor Score 2.5 / 5.0
Liquidity
C
Factor Score 2.2 / 5.0
Risk
C+
Factor Score 2.5 / 5.0
Momentum
D+
Factor Score 1.5 / 5.0
Yield
C+
Factor Score 2.5 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

Avg Volume 3.8K
Beta N/A
Max Drawdown N/A
Price Return 3M -7.0%
Price Return 12M -39.0%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-08-05 C+ (2.5) C (2.2) C+ (2.5) D+ (1.5) C+ (2.5) C- (2.1)
2026-08-04 C+ (2.5) C (2.2) C+ (2.5) D (1.3) C+ (2.5) C- (2.1)
2026-08-03 B- (3.0) C (2.3) C+ (2.7) D (1.4) C+ (2.5) C (2.3)
2026-08-02 B- (3.0) C (2.3) C+ (2.7) D (1.4) C+ (2.5) C (2.3)